Loading...

Home
ETF
BVS

BVS

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

BVS News

Bioventus (BVS) Q1 2026 Earnings Transcript

5d agoNASDAQ.COM

Bioventus Q1 2026 Earnings Call Highlights

5d agoseekingalpha

Bioventus Q1 Earnings Exceed Expectations

5d agoseekingalpha

Bioventus Reports 7% Revenue Growth in Q1

5d agoNewsfilter

TELA Bio Announces Board Refreshment Plan for Growth

Apr 30 2026Globenewswire

Bioventus Q4 2025 Earnings Call Highlights

Mar 05 2026seekingalpha

Bioventus (BVS) Q4 2025 Earnings Call Transcript

Mar 05 2026NASDAQ.COM

Bioventus Reports Q4 2025 Financial Results with Strong Growth

Mar 05 2026Newsfilter

Bioventus Releases Financial Guidance for FY 2026

Mar 05 2026seekingalpha

Wall Street Analysts Adjust Ratings on Key Stocks

Feb 09 2026Benzinga

BIOVENTUS INC: BARRINGTON RESEARCH STARTS COVERAGE WITH OUTPERFORM RATING AND SETS PRICE TARGET AT $13

Feb 09 2026moomoo

Bravura Solutions Projects FY2026 Revenue of A$265-275 Million Amid Insider Buying

Jan 01 2026Yahoo Finance

BioVersys Initiates BV100 Phase 3 Clinical Trial, Raises CHF 76.7 Million in IPO

Dec 11 2025Globenewswire

Halper Sadeh Investigates Bioventus for Potential Shareholder Compensation

Dec 05 2025PRnewswire

Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products

Jul 30 2025Newsfilter

Cantor Fitzgerald Initiates Coverage On Bioventus with Overweight Rating, Announces Price Target of $12

Jul 07 2025Benzinga